<description>&lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this week's podcast, &lt;em&gt;Neurology Today&lt;/em&gt;'s editor-in-chief highlights articles on the pros and cons of virtual neurology education, the FDA approval of tirzepatide for obesity-related obstructive sleep apnea, and the promise of AI for glioma assessment. &lt;span style= "mso-spacerun: yes;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</description>

Neurology Today in 5

American Academy of Neurology

Remote neurology education, tirzepatide for obesity-related OSA, artificial intelligence for glioma assessment

FEB 6, 20254 MIN
Neurology Today in 5

Remote neurology education, tirzepatide for obesity-related OSA, artificial intelligence for glioma assessment

FEB 6, 20254 MIN

Description

In this week's podcast, Neurology Today's editor-in-chief highlights articles on the pros and cons of virtual neurology education, the FDA approval of tirzepatide for obesity-related obstructive sleep apnea, and the promise of AI for glioma assessment.